TScan Therapeutics Enters Material Agreement

Ticker: TCRX · Form: 8-K · Filed: 2024-04-17T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, financial-condition

TL;DR

TScan Therapeutics signed a big deal on 4/16, more details to come.

AI Summary

TScan Therapeutics, Inc. announced on April 16, 2024, that it entered into a Material Definitive Agreement. The company also reported on its Results of Operations and Financial Condition. Specific details regarding the agreement and financial results were not provided in this initial filing.

Why It Matters

This filing indicates a significant business development for TScan Therapeutics, potentially impacting its future operations and financial standing.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities that may affect the company's financial performance and stock price.

Key Players & Entities

TScan Therapeutics, Inc. (company) — Registrant
April 16, 2024 (date) — Date of earliest event reported
880 Winter Street (address) — Business and Mail Address
Waltham (city) — Business and Mail City
Massachusetts (state) — Business and Mail State
02451 (zip_code) — Business and Mail Zip
(857) 399-9500 (phone_number) — Business Phone

FAQ

What is the nature of the Material Definitive Agreement entered into by TScan Therapeutics?

The filing states that TScan Therapeutics, Inc. entered into a Material Definitive Agreement on April 16, 2024, but does not provide specific details about the agreement itself.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on April 16, 2024.

What is TScan Therapeutics, Inc.'s principal executive office address?

TScan Therapeutics, Inc.'s principal executive offices are located at 880 Winter Street, Waltham, Massachusetts 02451.

What is the company's telephone number?

The company's telephone number, including area code, is (857) 399-9500.

What are the main items reported in this 8-K filing?

This 8-K filing reports on the Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, and Financial Statements and Exhibits.

From the Filing

0001193125-24-098509.txt : 20240417 0001193125-24-098509.hdr.sgml : 20240417 20240417062533 ACCESSION NUMBER: 0001193125-24-098509 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 22 CONFORMED PERIOD OF REPORT: 20240416 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240417 DATE AS OF CHANGE: 20240417 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 24849333 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 d816959d8k.htm 8-K 8-K false 0001783328 0001783328 2024-04-16 2024-04-16     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 16, 2024     TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-40603   82-5282075 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   830 Winter Street , Waltham , Massachusetts   02451 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code (857) 399-9500 Not Applicable (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trade Symbol(s)   Name of each exchange on which registered Voting Common Stock, $0.0001 par value per share   TCRX   The Nasdaq Global Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01. Entry into a Material Definitive Agreement On April 16, 2024, TScan Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and TD Securities (USA) LLC, as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 2,472,581 shares (the “Firm Shares”) of its voting common stock, par value $0.0001